Study at a glance
Do vitamin D supplements change blood signs of inflammation?
Researchers examined whether vitamin D supplements change selected blood signs of inflammation. The main analysis included 1,054 older adults in the VITAL trial, assigned vitamin D3 or placebo. Their average age was about 65, and only 17% started with vitamin D below 20 ng/mL. This was not a trial limited to people with very low vitamin D.
Which inflammation measurements changed with vitamin D3?
After two years, one inflammation-related marker, C-reactive protein measured with a high-sensitivity test, was lower with vitamin D3. The other three markers did not show significant effects. After four years, none showed a significant treatment effect. The precise size of the two-year change needs caution because two ways of expressing the published result give slightly different percentages. Neither percentage describes a reduction in heart attacks or strokes.
Why is the vitamin D and inflammation finding limited?
Fewer samples were available after four years, and many measurements of one marker could not be used. A separate analysis excluding some participants based on pill use did not meet the same statistical standard after allowing for multiple tests. The researchers did not establish that people with lower starting vitamin D benefited more. A separate one-year VITAL analysis found no reduction in its three markers, and one rose. That result alone does not show harm to health.
Do these results show lasting protection against heart attacks or strokes?
The studies used different selected groups and some different measurements. They do not show a simple sequence in which inflammation rises, falls and returns. Observational links between low vitamin D and later heart and circulation problems also do not prove that supplements will reduce those problems. The evidence supports a limited two-year blood-marker finding, not a broad, lasting reduction in inflammation or a dose or blood target for preventing heart attacks and strokes.
Read the full article below ↓Low vitamin D status, inflammatory blood markers and cardiovascular events measure different things. The VITAL biomarker studies tested whether assigned supplements changed selected inflammatory markers. Their results differed across markers and follow-up times, and did not establish cardiovascular protection from a marker change. For the detailed methods and appraisal, read Vitamin D Status, Inflammation and Cardiovascular Risk Markers: Full Study.
Why low status does not prove a treatment benefit
In the Framingham Offspring cohort, Wang and colleagues followed 1,739 adults without prior cardiovascular disease. Low baseline vitamin D was associated with later cardiovascular events: below 15 ng/mL, the adjusted hazard ratio was 1.62, with a 95% confidence interval of 1.11-2.36, compared with higher concentrations.
That hazard ratio describes relative occurrence over follow-up. It is not the proportion of participants who had an event or a predicted percentage benefit from supplements.
This was an observational association, not a supplementation experiment. Participants with different vitamin D concentrations could differ in other ways affecting risk. The distinction between vitamin D status and vitamin D effect explains why raising a blood concentration cannot be assumed to reverse an observed risk association.
What the principal biomarker study tested
Dong and colleagues analysed 1,054 Boston-area participants in VITAL, a randomised, blinded trial. They compared daily vitamin D3 at 2,000 IU with placebo, within a design that also separately assigned marine omega-3 fatty acids. The average participant was about 65 years old. Only 17% had baseline vitamin D concentrations below 20 ng/mL.
The researchers measured high-sensitivity C-reactive protein, hs-CRP, and three cytokines: IL-6, IL-10 and TNF-α. Cytokines are signalling proteins. These selected blood markers do not represent every aspect of inflammatory signalling within tissues. Samples were assessed at baseline, two years and four years.
What changed, and what did not
Vitamin D3 was associated with a lower hs-CRP trajectory at two years. The nominal P value was 0.007, and the result remained significant after the study’s correction for testing four markers. The other three markers did not show significant vitamin D effects. At four years, none of the four markers showed a significant treatment effect.
The authors described the two-year hs-CRP result as a 19% reduction. Their rounded log-scale coefficient corresponds to about 16% under the usual conversion, so the precise percentage needs caution. Neither percentage is a measured reduction in heart attacks or strokes. The Full Study explains this reporting nuance and the distinction between a marker and a clinical outcome.
Why the qualifications matter
There were 977 samples at year two and 685 at year four, compared with 1,051 at baseline. In addition, 29% of IL-6 measurements fell outside the assay’s quantification limits and were excluded. These limitations affect how confidently the later and marker-specific findings can be interpreted.
An analysis excluding participants with low adherence or substantial outside supplementation retained the direction of the two-year hs-CRP finding, but did not remain significant after multiple-comparison correction. Exploratory subgroup analyses also did not establish a different treatment effect according to baseline vitamin D status or the other investigated characteristics.
How the earlier results compare
Costenbader and colleagues studied 1,561 VITAL participants with paired baseline and one-year samples. Vitamin D did not significantly lower hs-CRP, IL-6 or TNFR2, a receptor-related marker distinct from TNF-α. IL-6 instead showed a net relative increase of about 8.2%, with a 95% confidence interval of 1.5%-15.3%. This does not by itself demonstrate clinical harm.
The earlier and later analyses used different selected cohorts, sample handling and some different markers. Their findings cannot establish a simple sequence in which inflammation rises at one year, falls at two years and returns at four years.
What readers can conclude
The relevance to heart physiology is that inflammatory signals, vitamin D status and clinical events need separate evidence. The trials support a limited two-year hs-CRP finding, not a uniform anti-inflammatory effect or proven cardiovascular prevention. They do not define a supplement dose or blood target for preventing heart attacks and strokes.
Scientific sources
Dong Y, Zhu H, Chen L, Huang Y, Christen W, Cook NR, Copeland T, Mora S, Buring JE, Lee IM, Costenbader KH, Manson JE. Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial. Nutrients. 2022;14(24):5307. DOI: 10.3390/nu14245307. PMID: 36558465. Principal appraisal, including the supplementary subgroup figure.
Costenbader KH, MacFarlane LA, Lee IM, Buring JE, Mora S, Bubes V, Kotler G, Camargo CA Jr, Manson JE, Cook NR. Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. Clinical Chemistry. 2019;65(12):1508-1521. DOI: 10.1373/clinchem.2019.306902. PMID: 31699704. Earlier VITAL biomarker comparison.
Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS. Vitamin D Deficiency and Risk of Cardiovascular Disease. Circulation. 2008;117(4):503-511. DOI: 10.1161/CIRCULATIONAHA.107.706127. PMID: 18180395. Observational background; the cohort finding is used to distinguish association from intervention evidence.
Related reading
Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial
Background: The VITAL study was a nationwide, randomized, double-blind, placebo-controlled, 2 × 2 factorial trial of vitamin D3 (2000 IU/day) and marine n-3 FAs (1 g/day) supplements.
Original paper ↗Read more →Vitamin D Status, Inflammation and Cardiovascular Risk Markers: Full Study
Examine vitamin D status, cardiovascular associations and VITAL inflammation results, with study methods, conflicting findings and limits of biomarker evidence.
Read more →3′‐Sialyllactose Prevents Atherosclerosis by Attenuating Chronic Inflammation via the Gut‐Immune‐Cardiovascular Axis in LDLR −/− Mice
Herein, 40 male low‐density lipoprotein receptor knockout (LDLR −/−) mice were randomized into five groups: normal diet (ND), high‐cholesterol diet (HCD), and three 3′‐SL groups (low dose SLL, medium dose SLM, high dose SLH).
Original paper ↗Read more →Inflammation and Vitamin D Receptor Polymorphism: Impact on All-Cause and Cardiovascular Mortality in Mexican Women on Dialysis
This study aimed to determine how these factors affect mortality.
Original paper ↗Read more →Vitamin D and inflammatory markers: cross-sectional analyses using data from the English Longitudinal Study of Ageing (ELSA)
Our findings showed that 25(OH)D levels were associated with two out the three inflammatory markers investigated.
Original paper ↗Read more →High-Sensitivity C-Reactive Protein Relationship with Metabolic Disorders and Cardiovascular Diseases Risk Factors
Background.
Original paper ↗Read more →Cardiac tissue oxidative stress and inflammation after vitamin D administrations in high fat: diet induced obese rats
The current study was aimed to evaluate the effects of vitamin D administration on the markers of oxidative stress and inflammation in the cardiac tissue of high-fat diet induced obese rats.
Original paper ↗Read more →Supplemental 25-hydroxycholecalciferol Alleviates Inflammation and Cardiac Fibrosis in Hens
Broiler breeder hens with efficient feed conversion rate under restricted feed intake (R-hens) or allowed unlimited access to feed (Ad-hens) progressed with cardiac functional failure and suffered early sudden death.
Original paper ↗Read more →Vitamin D supplementation and cardiac tissue inflammation in obese rats
The current study was aimed to evaluate the effects of active form of vitamin D on TGF: β, NF-κB and MCP-1 in heart tissue of obese rats.
Original paper ↗Read more →Evaluation of nutritional interventions and their impact on metabolic syndrome risk markers in older adults
The aim of the study was to assess the effects of documented nutritional intervention on the metabolic syndrome risk markers in older adults based on real-world clinical data.
Original paper ↗Read more →Cumulative Inflammation and HbA1c Levels Correlate with Increased Intima-Media Thickness in Patients with Severe Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that has been associated with a greater risk of metabolic and cardiovascular comorbidities.
Original paper ↗Read more →Effects of Biologic Therapies and Narrowband UVB Phototherapy on Vascular Inflammation and Systemic Inflammatory Biomarkers in Psoriasis: A Systematic Review and Narrative Synthesis of Prospective Studies
We aimed to systematically synthesize prospective evidence on treatment-associated changes in vascular inflammation and systemic inflammatory biomarkers in adults with moderate-to-severe psoriatic disease.
Original paper ↗Read more →The Relationship between Selected Inflammation and Oxidative Stress Biomarkers and Carotid Intima-Media Thickness (IMT) Value in Youth with Type 1 Diabetes Co-Existing with Early Microvascular Complications
Recent years have confirmed the importance of oxidative stress and biomarkers of inflammation in estimating the risk of cardiovascular disease (CVD) and explaining not fully understood pathogenesis of diabetic macroangiopathy.
Original paper ↗Read more →Associations of 25 Hydroxyvitamin D and High Sensitivity C-reactive Protein Levels in Early Life
We investigated the association between longitudinal measurements of 25(OH)D and hs-CRP, respectively, from pregnancy to childhood and throughout childhood in two Danish mother: child cohorts, the COPSAC2010 and COPSAC2000.
Original paper ↗Read more →A comparative study of the injury patterns and inflammatory response between suicidal and unintentional falls from height in Germany
This study aims to analyse injury patterns, inflammatory responses and complication rates in people who have jumped to their death, compared to those who have fallen unintentionally.
Original paper ↗Read more →New circulating biomarkers for predicting cardiovascular death in healthy population
Of 82 participants, 17 died by CVD causes.
Original paper ↗Read more →Non-Skeletal Roles of Vitamin D in Skin, Gut, and Cardiovascular Disease: Focus on Epithelial Barrier Function and Immune Regulation in Chronic Disease
Vitamin D is increasingly recognized as a key regulator of epithelial barrier integrity and mucosal immune homeostasis, with implications extending far beyond skeletal health.
Original paper ↗Read more →The Role of Vitamin D and Its Molecular Bases in Insulin Resistance, Diabetes, Metabolic Syndrome, and Cardiovascular Disease: State of the Art
In the last decade, an increasing awareness was directed to the role of Vitamin D in non-skeletal and preventive roles for chronic diseases.
Original paper ↗Read more →The vitamin D-cardiovascular nexus unraveling mechanistic promise and trial reality
In contrast, large-scale randomized trials and their meta-analyses have uniformly failed to demonstrate significant cardiovascular benefit from vitamin D supplementation in the general population.
Original paper ↗Read more →Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM/BiomarCaRE consortium
Over a median follow-up of 13.8 years, a total of 652 (17.0%) and 5524 (6.1%) cases of incident heart failure were observed in participants with and without diabetes, respectively.
Original paper ↗Read more →Elevated Macrophage Migration Inhibitory Factor 1 Is Associated with Left and Right Ventricular Systolic Dysfunction in Heart Failure with Reduced Ejection Fraction
We evaluated 70 hemodynamically stable patients with left ventricular EF (LVEF) < 50% by means of echocardiography and blood sampling.
Original paper ↗Read more →Original sources
Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial
Background: The VITAL study was a nationwide, randomized, double-blind, placebo-controlled, 2 × 2 factorial trial of vitamin D3 (2000 IU/day) and marine n-3 FAs (1 g/day) supplements.
Publication details
Dong Y, Zhu H, Chen L, Huang Y, Christen W, Cook NR, Copeland T, Mora S, Buring JE, Lee IM, Costenbader KH, Manson JE. Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial. Nutrients. 2022;14(24):5307. DOI: 10.3390/nu14245307. PMID: 36558465. Principal appraisal, including the supplementary subgroup figure.
Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults
Published in Clinical Chemistry (2019).
Publication details
Costenbader KH, MacFarlane LA, Lee IM, Buring JE, Mora S, Bubes V, Kotler G, Camargo CA Jr, Manson JE, Cook NR. Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. Clinical Chemistry. 2019;65(12):1508-1521. DOI: 10.1373/clinchem.2019.306902. PMID: 31699704. Earlier VITAL biomarker comparison.
Vitamin D Deficiency and Risk of Cardiovascular Disease
Published in Circulation (2008).
Publication details
Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS. Vitamin D Deficiency and Risk of Cardiovascular Disease. Circulation. 2008;117(4):503-511. DOI: 10.1161/CIRCULATIONAHA.107.706127. PMID: 18180395. Observational background; the cohort finding is used to distinguish association from intervention evidence.